Canadian Cancer Society. Lung and bronchus cancer statistics. November 2023. Available at: https://cancer.ca/en/cancer-information/cancer-types/lung/statistics. Accessed: 20 Feb 2024. 2023.

Cancer Care Ontario. Ontario Cancer Statistics 2022. Ch 1: Estimated Current Cancer Incidence. Available at: https://www.cancercareontario.ca/en/data-research/view-data/statistical-reports/ontario-cancer-statistics-2022/ch-1-estimated-current-cancer-incidence-2022#:~:text=%5B11%2C12%5D-,Incidence%20by%20Cancer%20Type,11.1%25)%20(Table%201.1). Accessed: 20 Feb 2024. 2022.

Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics: A 2020 special report on lung cancer. Available at: www.cancer.ca/Canadian-Cancer-Statistics-2020-EN. Accessed: 20 Feb 2024. 2020.

Linehan V, Harris S, Bhatia R. An audit of opportunistic lung cancer screening in a Canadian province. J Prim Care Commun Health. 2021;12:21501327211051484.

Article  Google Scholar 

Darling GE, Tammemägi MC, Schmidt H, et al. Organized lung cancer screening pilot: informing a province-wide program in Ontario. Canada Ann Thorac Surg. 2021;111(6):1805–11.

Article  PubMed  Google Scholar 

Tammemagi MC, Schmidt H, Martel S, et al. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study. Lancet Oncol. 2017;18(11):1523–31.

Article  PubMed  Google Scholar 

Kris MG, Gaspar LE, Chaft JE, et al. Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non-small-cell lung cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. J Clin Oncol. 2017;35(25):2960–74.

Article  PubMed  Google Scholar 

Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(4):iv1–21.

Article  CAS  PubMed  Google Scholar 

Alberta Health Services. Cancer Guidelines. Guideline Resource Unit (GURU), Information for Health Professionals. Lung Treatment Guidelines LU-001, LU-002, LU-003. Non-small Cell Lung Cancer Stages I, II, and III. Last updated: 2012–2014. Available at: https://www.albertahealthservices.ca/info/cancerguidelines.aspx. Accessed: 20 Aug 2021. 2021.

Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552–9.

Article  PubMed  Google Scholar 

Plunkett TA, Chrystal KF, Harper PG. Quality of life and the treatment of advanced lung cancer. Clin Lung Cancer. 2003;5(1):28–32.

Article  PubMed  Google Scholar 

Zarogoulidis K, Zarogoulidis P, Darwiche K, et al. Treatment of non-small cell lung cancer (NSCLC). J Thorac D. 2013;5(Suppl 4):S389–96.

Google Scholar 

Mieras A, Pasman HRW, Klop HT, et al. What goals do patients and oncologists have when starting medical treatment for metastatic lung cancer? Clin Lung Cancer. 2021;22(3):242-51.e5.

Article  PubMed  Google Scholar 

Hanna NH, Schneider BJ, Temin S, et al. Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) Joint Guideline update. J Clin Oncol. 2020;38(14):1608–32.

Article  PubMed  Google Scholar 

Hanna NH, Robinson AG, Temin S, et al. Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) Joint Guideline update. J Clin Oncol. 2021;39(9):1040–91.

Article  CAS  PubMed  Google Scholar 

Šutić M, Vukić A, Baranašić J, et al. Diagnostic, predictive, and prognostic biomarkers in non-small cell lung cancer (NSCLC) management. J Pers Med. 2021;11(11):1102.

Article  PubMed  PubMed Central  Google Scholar 

Villalobos P, Wistuba II. Lung cancer biomarkers. Hematol Oncol Clin North Am. 2017;31(1):13–29.

Article  PubMed  PubMed Central  Google Scholar 

Mariano C, Bosdet I, Karsan A, et al. A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease. Lung Cancer. 2014;83(1):73–7.

Article  PubMed  Google Scholar 

Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892–911.

PubMed  PubMed Central  Google Scholar 

Ellis PM, Verma S, Sehdev S, Younus J, Leighl NB. Challenges to implementation of an epidermal growth factor receptor testing strategy for non-small-cell lung cancer in a publicly funded health care system. J Thorac Oncol. 2013;8(9):1136–41.

Article  CAS  PubMed  Google Scholar 

Shiau CJ, Babwah JP, da Cunha SG, et al. Sample features associated with success rates in population-based EGFR mutation testing. J Thorac Oncol. 2014;9(7):947–56.

Article  PubMed  Google Scholar 

Graham RP, Treece AL, Lindeman NI, et al. Worldwide frequency of commonly detected EGFR mutations. Arch Pathol Lab Med. 2018;142(2):163–7.

Article  CAS  PubMed  Google Scholar 

Melosky B, Banerji S, Blais N, et al. Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer. Curr Oncol. 2020;27(2):e146–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang YL, Yuan JQ, Wang KF, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985–93.

Article  PubMed  PubMed Central  Google Scholar 

Kuruvilla MS, Liu G, Syed I, et al. EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada. Lung Cancer. 2022;173:58–66.

Article  Google Scholar 

Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19(1):139–48.

Article  CAS  PubMed  Google Scholar 

Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for Stage II-IIIA (N1–N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 Phase III trial. J Clin Oncol. 2021;39(7):713–22.

Article  CAS  PubMed  Google Scholar 

Kelly K, Altorki NK, Eberhardt WE, et al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind. Phase III trial J Clin Oncol. 2015;33(34):4007–14.

CAS  PubMed  Google Scholar 

Xu ST, Xi JJ, Zhong WZ, et al. The unique spatial-temporal treatment failure patterns of adjuvant gefitinib therapy: a post hoc analysis of the ADJUVANT trial (CTONG 1104). J Thorac Oncol. 2019;14(3):503–12.

Article  CAS  PubMed  Google Scholar 

Pennell NA, Neal JW, Chaft JE, et al. SELECT: A Phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer. J Clin Oncol. 2019;37(2):97–104.

Article  CAS  PubMed  Google Scholar 

Goss GD, O’Callaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol. 2013;31(27):3320–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin C, Hu F, Chu H, et al. The role of EGFR-TKIs as adjuvant therapy in EGFR mutation-positive early-stage NSCLC: a meta-analysis. Thorac Cancer. 2021;12(7):1084–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li N, Ou W, Ye X, et al. Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study. Ann Surg Oncol. 2014;21(6):2091–6.

Article  PubMed  Google Scholar 

Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383(18):1711–23.

Article  CAS  PubMed  Google Scholar 

AstraZeneca. Press release: Tagrisso demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer. 9 March 2023. Available at: https://www.astrazeneca.com/media-centre/press-releases/2023/tagrisso-demonstrated-strong-overall-survival-benefit-in-the-adaura-phase-iii-trial.html. Accessed: 24 Apr 2023. 2023

Herbst RS, Wu Y-L, John T, et al. Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non–small-cell lung cancer: updated results from the phase III randomized ADAURA trial. J Clin Oncol. 2023;41(10):1830–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

AstraZeneca (2024) Product Monograph. TAGRISSO(R) (osimertinib tablets). Date of Revision: Jan 02, 2024. Available at: https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/tagrisso-product-monograph-en.pdf. Accessed: 16 Feb 2024

European Medicines Agency (2023) Summary of product characteristics for TAGRISSO. Last updated: 20 Nov 2023. Available at: https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf. Accessed: 20 Feb 2024

Food and Drug Administration (2024) Highlights of prescribing information for TAGRISSO (osimertinib) tablets. Revised: 03/2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Accessed: 20 Feb 2024

de Scordilli M, Michelotti A, Bertoli E, De Carlo E, Del Conte A, Bearz A. Targeted therapy and immunotherapy in early-stage non-small cell lung cancer: current evidence and ongoing trials. Int J Mol Sci. 2022;23(13):7222.

Article  PubMed  PubMed Central  Google Scholar 

Catania C, Muthusamy B, Spitaleri G, Del Signore E, Pennell NA. The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. a review of the literature. Clin Lung Cancer. 2022;23(2):108–15.

Article  CAS  PubMed  Google Scholar 

Chaft JE, Rimner A, Weder W, Azzoli CG, Kris MG, Cascone T. Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer. Nat Rev Clin Oncol. 2021;18(9):547–57.

Article  CAS  PubMed  PubMed Central